Sell-side analysts are offering a consensus “Buy” rating on shares of Toll Brothers, Inc. (NYSE:TOL). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 2.20. Based on a recent trade, the shares are hovering around $39.67 which, according to analysts, yield significant upside potential to the $40.93 consensus target price.
Toll Brothers, Inc. (NYSE:TOL)’s shares may have a significant upside to the consensus target of 40.93, but how has it been performing relative to the market? The stock’s price is 39.67 and their relative strength index (RSI) stands at 68.03. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
Toll Brothers, Inc. (NYSE:TOL) shares are moving 2.37% trading at $39.67 today.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 2.30. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $16.77 also implies significant upside from the current price of $14.50.
At the time of writing, the stock was trading at $14.50. This represents a change from most recent open price of 1.75%. In terms of performance, year to date, the stock is 43.42%. The monthly stock performance comes in at 0.07%. For the quarter, shares are performing at -1.67%. Weekly performance analysis shows the equity at 10.27%.
In taking a look at technical levels, shares are trading 9.29% away from the 50 day simple moving average and 19.42% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -4.61% away from it’s 52- week high and 88.31% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Halozyme Therapeutics, Inc.’s RSI stands at 69.68. In looking at volatility levels, the shares saw weekly volatility of 3.91% and 3.88% over the past month.